Betaxolol - Revision history

Elcatracho: /* See Also */

2021-03-07T01:24:57Z

ClaireLewis at 21:33, 19 September 2019

2019-09-19T21:33:40Z

← Older revision		Revision as of 21:33, 19 September 2019
Line 58:		Line 58:
	<references/>		<references/>
	[[Category:Pharmacology]]		[[Category:Pharmacology]]
			[[Category:Cardiology]]

Humanguy: edited dosage forms, strengths, routes of administration, trade names

2017-10-11T22:56:14Z

edited dosage forms, strengths, routes of administration, trade names

← Older revision		Revision as of 22:56, 11 October 2017
Line 1:		Line 1:
	==Administration==		==Administration==
	*Type: [[Beta blocker]]		*Type: [[Beta blocker]]
	*Dosage Forms: 10 mg, 20 mg, 0.5% ophthalmic ~~solution,~~ 0.25% ~~suspension~~		*Dosage Forms: tablet, ophthalmic solution, ophthalmic suspension
	*Routes of Administration: ~~Oral~~, ophthalmic		*Dosage Stregths: tablet: 10 mg, 20 mg; ophthalmic solution: 0.5%; ophthalmic suspension: 0.25%
	*Common Trade Names: Kerlone		*Routes of Administration: PO, ophthalmic
			*Common Trade Names: Kerlone, Betoptic, Betoptic S

	==Adult Dosing==		==Adult Dosing==

ClaireLewis at 02:20, 11 December 2016

2016-12-11T02:20:29Z

← Older revision		Revision as of 02:20, 11 December 2016
Line 1:		Line 1:
	==Administration==		==Administration==
	*Type: [[Beta blocker]]		*Type: [[Beta blocker]]
	*Dosage Forms: 10, 20 mg		*Dosage Forms: 10 mg, 20 mg, 0.5% ophthalmic solution, 0.25% suspension
	*Routes of Administration: Oral		*Routes of Administration: Oral, ophthalmic
	*Common Trade Names: Kerlone		*Common Trade Names: Kerlone

	==Adult Dosing==		==Adult Dosing==
	*10-20 mg PO qd		*5-80 mg PO daily
	**Start: 10 mg PO qd		*1-2 drops in affected eye BID
	**Max: 40 mg/day
	**Consider starting 5 mg PO qd in ~~elderly pts~~
	**Taper dose over 2 weeks to D/C

	==Pediatric Dosing==		==Pediatric Dosing==
	N/A		''Safety/efficacy of oral forms and 0.5% solution not established in peds''
			*0.25% suspension: 1 drop in affected eye BID

	==Special Populations==		==Special Populations==
	*[[Drug Ratings in Pregnancy\|Pregnancy Rating]]: C; Caution advised in 2nd and 3rd trimesters. Risk of intrauterine growth restriction and neonatal adverse effects including bradycardia and hypoglycemia.		*[[Drug Ratings in Pregnancy\|Pregnancy Rating]]: C; Caution advised in 2nd and 3rd trimesters. Risk of intrauterine growth restriction and neonatal adverse effects including bradycardia and hypoglycemia.
	*[[Lactation risk categories\|Lactation risk]]: L3; Safety unknown		*[[Lactation risk categories\|Lactation risk]]: L3; Safety unknown
			*Severe renal impairment: Start at 5mg PO daily, increase by 5mg/day q2wk to max daily dose 20mg
	~~===Renal Dosing===~~		*Hepatic dosing: no adjustment
	*~~Adult:~~ Severe impairment: Start ~~5 mg~~ PO ~~qd. May~~ increase by ~~5 mg~~/day ~~q 2 weeks~~ to max ~~20 mg/day.~~
	*~~Pediatric: N/A~~

	~~===~~Hepatic ~~Dosing===~~
	*Adult: ~~No adjustement~~
	*Pediatric: N/A

	==Contraindications==		==Contraindications==
	*Allergy to class/drug		*Allergy to class/drug
	*Sinus [[bradycardia]]		*Sinus [[bradycardia]], 2nd or 3rd degree [[AV block]], [[sick sinus syndrome]] (without pacemaker)
	*2nd or 3rd degree [[AV block]]		*Decompensated [[heart failure]], [[cardiogenic shock]]
	*Decompensated [[heart failure]]		*Untreated [[pheochromocytoma]]
	*[[~~Cardiogenic~~ shock]]
	*[[~~Sick sinus syndrome]] w/o pacemaker~~
	*[[Pheochromocytoma]]~~, untreated~~
	*Avoid abrupt withdrawal		*Avoid abrupt withdrawal

Line 40:		Line 29:
	===Serious===		===Serious===
	*[[CHF]]		*[[CHF]]
	*[[~~Bradycardia~~]], ~~severe~~		*Severe [[bradycardia]], [[heart block]]
	*[[~~Heart~~ block]]		*[[Angina]] exacerbation, ventricular arrythmia, or [[MI]] with abrupt discontinuation
	*[[Angina]] exacerbation ~~with abrupt D/C~~
	*[[MI]] ~~if abrupt D/C~~
	*Ventricular arrhythmia if abrupt ~~D/C~~
	*Bronchospasm		*Bronchospasm
	*Hypersensitivity reaction		*Hypersensitivity reaction
	*Raynaud's phenomenon		*[[Psoriasis]] exacerbation, [[lupus]] erythematosus, Raynaud's phenomenon
	*[[Psoriasis]] exacerbation
	*[[~~Lupus~~]] erythematosus

	===Common===		===Common===
	*[[Bradycardia]]		*[[Bradycardia]], [[chest pain]]
	*[[Headache]]		*[[Headache]], [[dizziness]], [[fatigue]]
	*[[Dyspepsia]]		*[[Dyspepsia]], [[diarrhea]]
	*[[~~Dizziness~~]]
	*[[Arthralgia]]		*[[Arthralgia]]
	*[[~~Fatigue]]~~		*[[URI]], [[pharyngitis]]
	*[[Lethargy]]
	*[[~~URI~~]]
	*[[Dyspnea]]		*[[Dyspnea]]
	*[[Chest pain]]
	*[[Pharyngitis]]
	*[[Diarrhea]]

	==Pharmacology==		==Pharmacology==
Line 71:		Line 48:

	==Mechanism of Action==		==Mechanism of Action==
	Selectively antagonizes beta-1 adrenergic receptors.		*Selectively antagonizes beta-1 adrenergic receptors.

	==Comments==		==Comments==

	==See Also==		==See Also==
			*[[Beta-blockers]]
	==References==		==References==
	<references/>		<references/>
	[[Category:Pharmacology]]		[[Category:Pharmacology]]

Jonwarren: Creation of page

2016-11-24T01:55:38Z

Creation of page

New page

==Administration==
*Type: [[Beta blocker]]
*Dosage Forms: 10, 20 mg
*Routes of Administration: Oral
*Common Trade Names: Kerlone

==Adult Dosing==
*10-20 mg PO qd
**Start: 10 mg PO qd
**Max: 40 mg/day
**Consider starting 5 mg PO qd in elderly pts
**Taper dose over 2 weeks to D/C

==Pediatric Dosing==
N/A

==Special Populations==
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: C; Caution advised in 2nd and 3rd trimesters. Risk of intrauterine growth restriction and neonatal adverse effects including bradycardia and hypoglycemia.
*[[Lactation risk categories|Lactation risk]]: L3; Safety unknown

===Renal Dosing===
*Adult: Severe impairment: Start 5 mg PO qd. May increase by 5 mg/day q 2 weeks to max 20 mg/day.
*Pediatric: N/A

===Hepatic Dosing===
*Adult: No adjustement
*Pediatric: N/A

==Contraindications==
*Allergy to class/drug
*Sinus [[bradycardia]]
*2nd or 3rd degree [[AV block]]
*Decompensated [[heart failure]]
*[[Cardiogenic shock]]
*[[Sick sinus syndrome]] w/o pacemaker
*[[Pheochromocytoma]], untreated
*Avoid abrupt withdrawal

==Adverse Reactions==
===Serious===
*[[CHF]]
*[[Bradycardia]], severe
*[[Heart block]]
*[[Angina]] exacerbation with abrupt D/C
*[[MI]] if abrupt D/C
*Ventricular arrhythmia if abrupt D/C
*Bronchospasm
*Hypersensitivity reaction
*Raynaud's phenomenon
*[[Psoriasis]] exacerbation
*[[Lupus]] erythematosus

===Common===
*[[Bradycardia]]
*[[Headache]]
*[[Dyspepsia]]
*[[Dizziness]]
*[[Arthralgia]]
*[[Fatigue]]
*[[Lethargy]]
*[[URI]]
*[[Dyspnea]]
*[[Chest pain]]
*[[Pharyngitis]]
*[[Diarrhea]]

==Pharmacology==
*Half-life: 14-22 hr
*Metabolism: Liver extensively; CYP450: Unknown
*Excretion: Urine > 80% (15% unchanged)

==Mechanism of Action==
Selectively antagonizes beta-1 adrenergic receptors.

==Comments==

==See Also==

==References==
<references/>
[[Category:Pharmacology]]

← Older revision		Revision as of 01:24, 7 March 2021
Line 55:		Line 55:
	==See Also==		==See Also==
	*[[Beta-blockers]]		*[[Beta-blockers]]
			*[[Beta-blocker toxicity]]
			*[[Antiarrhythmics]]
			*[[Antihypertensive medications]]

	==References==		==References==
	<references/>		<references/>
	[[Category:Pharmacology]]		[[Category:Pharmacology]]
	[[Category:Cardiology]]		[[Category:Cardiology]]